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DBackground: Advances in technology such as epicardial bipolar radiofrequency pulmonary vein isolation, gan-
glionated plexi identification, and isolation and thoracoscopic left atrial appendage exclusion have enabled less
invasive surgical options for management of atrial fibrillation.
Methods: We performed a prospective, nonrandomized study of consecutive patients with symptomatic parox-
ysmal atrial fibrillation undergoing a video-assisted, minimally invasive surgical ablation procedure. The proce-
dure consisted of bilateral, epicardial pulmonary vein isolation with bipolar radiofrequency, partial autonomic
denervation, and selective excision of the left atrial appendage. Minimum follow-up was 1 year with long-
term monitoring (24-hour continuous, 14-day event or pacemaker interrogation).
Results:BetweenMarch 2005 and January 2008, 52 patients (35 male), mean age 60.3 years (range, 42–79 years)
underwent the procedure. The left atrial appendage was isolated in 88.0% (44/50). Average hospital stay was 5.2
days (range 3–10 days). There were no operative deaths or major adverse cardiac events. On long-term monitor-
ing, freedom from atrial fibrillation/flutter/tachycardia was 86.3% (44/51) and 80.8% (42/52) at 6 and 12months,
respectively. Antiarrhythmic drugs were stopped in 33 of 37 patients and warfarin in 30 of 37 of the patients in
whom ablation was successful at 12 months. Freedom from symptoms attributed to atrial fibrillation/flutter/tachy-
cardia was 78.0% (39/50) at 6 months and 63.8% (30/47) at 12 months.
Conclusions: Minimally invasive surgical ablation is effective in the management of paroxysmal atrial fibril-
lation as evidenced by freedom from atrial arrythmias by long-term monitoring at 12 months. Measuring suc-
cess using clinical symptoms underestimated clinical success as compared with long-term monitoring. (J Thorac
Cardiovasc Surg 2010;140:823-8)Atrial fibrillation (AF) is a superventricular tachyarrhythmia
characterized by uncoordinated atrial activation and conse-
quent deterioration of mechanical function.1 With an
estimated prevalence of 0.4% to 1% in the general popula-
tion, AF is the most common cardiac arrhythmia encoun-
tered in clinical practice.2 AF is associated with an
increased long-term risk of stroke, heart failure, and all-
cause mortality.3 Clinical symptoms associated with AF
are quite variable in character and severity but are generally
manifested as decreased energy level, dyspnea, and palpita-
tions. Objectives for the management of AF are threefold:
rate control, prevention of thromboembolism, and correction
of the rhythm abnormality. So that these objectives can be
achieved, most patients are managed with antiarrhythmice Cardiopulmonary Research Science and Technology Institute (CRSTI),a
s, Tex, The Atrial Fibrillation Center at The Heart Hospital,b Plano, Tex,
he Medical City Dallas Hospital,c Dallas, Tex.
ures: James R. Edgerton reports consulting and lecture fees from Atricure.
d for publication Feb 9, 2009; revisions received Nov 17, 2009; accepted for
cation Nov 29, 2009; available ahead of print March 18, 2010.
for reprints: James R Edgerton, MD, 708 Alliance Blvd, Pavilion One, Suite
Plano, TX 75093 (E-mail: edgertonjr@aol.com).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2009.11.065
The Journal of Thoracic and Cadrugs (AADs) and anticoagulation to minimize the embolic
and hemodynamic sequelae of the condition.1
Haissaguerre and associates4 initially described spontane-
ous initiation of AF by ectopic beats originating in the pul-
monary veins. This led to the development of catheter-
based treatment strategies with the goal of electrical isolation
of the pulmonary veins.5 This technique was hampered by
the technical difficulty of achieving transmural electrical iso-
lation using endocardial catheter ablation. The feasibility of
pulmonary vein isolation by a minimally invasive surgical
approach was initially described by Wolf and associates.6
This procedure evolved into an epicardial bipolar radiofre-
quency ablation that includes isolation of the pulmonary
vein antrum, detection and ablation of ganglionated plexi
(GP), division of the ligament of Marshall, and removal of
the left atrial appendage (LAA).
The importance of the autonomic nervous system in the
initiation of AF was first described by Coumel7-9 in 1993.
GPs, found in atrial fat pads, have subsequently been shown
to play a role in initiation and maintenance of AF.10,11 More-
over, the ablation of these GPs has been demonstrated to
abolish vagally mediated AF.12
In addition to the GP, the ligament of Marshall has been
shown to contain sympathetic and parasympathetic nerverdiovascular Surgery c Volume 140, Number 4 823
Abbreviations and Acronyms
AADs ¼ antiarrhythmic drugs
AF ¼ atrial fibrillation
GP ¼ ganglionated (ganglionic) plexi
LAA ¼ left atrial appendage
LTM ¼ long-term monitoring
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Dtrunks important to cardiac autonomic function. Moreover,
patients with a well-developed ligament of Marshall have
been found to have an increased incidence of arrythmogenic
foci in the left superior pulmonary veins.13
Finally, to further enhance effectiveness in preventing
thromboembolism, exclusion or removal of the LAA is op-
timal. This is critical because thrombus material associated
with AF arises most commonly in the LAA. Decreased
flow within the LAA during AF (as evidenced by the forma-
tion of spontaneous echo contrast or ‘‘smoke’’) has also
been associated with embolic events.14
Herein, we describe our initial experience and outcomes
with a minimally invasive surgical procedure of pulmonary
vein isolation by bipolar radiofrequency, intraoperative con-
firmation of transmurality, mapping for and ablation of GPs,
and exclusion of the LAA.
METHODS
A nonrandomized series of consecutive patients with symptomatic par-
oxysmal AF were entered into the study. The study was approved by the In-
stitutional Review Boards of Medical City Hospital, Dallas, Texas, and
Baylor University Hospital, Dallas, Texas, and informed consent was ob-
tained from all patients. All definitions and reporting standards were in ac-
cordance with the 2007 Heart Rhythm Society (HRS)/European Heart
Rhythm Association (EHRA)/European Cardiac Arrhythmia Society
(ECAS) expert consensus statement for catheter and surgical ablation of
AF.15
Surgical Procedure
Surgery was performed with the patient under general anesthetia with
double-lumen endotracheal intubation for selective pulmonary ventilation.
Arterial blood pressure and pulmonary artery monitoring by a Swan–
Ganz catheter (Edwards LifeSciences, Irvine, Calif) was performed in all
patients. Transesophageal echocardiography was performed on the operat-
ing table before and during each procedure. In addition, patients with prior
catheter ablations underwent computed tomography or magnetic resonance
imaging of the left atrium before the procedure. The procedures were per-
formed through bilateral 5-cm anterior minithoracotomies in the third or
fourth intercostal space. Video assistance with a 5-mm 30 endoscope
was used. A sensing device was used to detect atrial electrical activity con-
ducted into the upper and lower right pulmonary veins and the bifurcation.
High-frequency stimulation at 12 volts at a cycle length of 50 ms and a pulse
width of 1 to 10 ms was used to map 13 areas for GPs (Figure 1). These lo-
cations were recorded for subsequent ablation. Detection and localization of
GPs were determined by evidence of a vagal response as defined by an in-
crease in the RR interval of greater than 50% from baseline. Circumferential
dissection of the right pulmonary veins with a lighted dissector was then per-
formed. A bipolar radiofrequency clamp (Atricure, Inc, Cincinnati, Ohio)
was then guided around the veins. The bipolar radiofrequency clamp was824 The Journal of Thoracic and Cardiovascular Surgthen used to perform wide antrum circumferential ablation. The ablation en-
ergy was delivered 3 to 5 times. Entrance block was confirmed by sensing
for atrial activity in the pulmonary veins. If atrial activity was detected, ab-
lation was readministered until entrance block was confirmed. Any of the 13
GP areas that still showed evidence of vagal innervation after application of
the ablation lines were then targeted for direct radiofrequency ablation using
a monopolar pen. On completion, a small-caliber surgical drain was placed
through the thoracoscopic site. The patient was then repositioned for opti-
mal access to the left side. Mirror-image surgical incisions were made.
Whereas the pericardium was opened anterior to the phrenic nerve on the
right side, it was opened posterior to the phrenic nerve on the left side.
The same sequence of pulmonary vein sensing for the detection of atrial ac-
tivity was performed first, followed by high-frequency stimulation for de-
tection of GPs, especially in the area of the ligament of Marshall. Areas
that showed evidence of vagal autonomic innervation were recorded on
a map that outlined 10 areas on the left side (Figure 2). The ligament ofMar-
shall was then divided and the pulmonary veins encircled as on the right
side. A bipolar radiofrequency clamp was then applied to perform wide an-
trum circumferential ablation. On confirmation of pulmonary vein entrance
block and targeted autonomic denervation, a drain was placed on the left
side.
After completion of the left-sided ablation, excision or exclusion of the
LAA was performed selectively. A variety of techniques were used to ex-
clude the appendage, including excision with an endoscopic stapler with
or without bovine pericardial support or simply staple exclusion of the
LAA. In cases in which it was deemed hazardous to perform the appendec-
tomy owing to anatomic constraints, the appendage was left intact. For all
patients having LAA exclusion, transesophageal echocardiography was
used to confirm that the exclusion was successful. If AF was present at
the end of the procedure, the patient was cardioverted to sinus rhythm.
The general anesthetic was reversed and the patient was extubated in the op-
erating room. The patient was monitored for the first 24 hours in the inten-
sive care unit.
Postoperatively, patients were returned to the same antiarrhythmic drug
regimen that they were using when seen preoperatively. This was restarted
as soon as they were able to resume receiving oral medication and was con-
tinued for the first 30 to 90 days.
Follow-up
Continuous telemetric monitoring was performed throughout the hospi-
tal stay and a 12-lead electrocardiogramwas obtained 1, 3, 6, and 12 months
after discharge. Long-term monitoring (LTM) by either a 24-hour Holter
monitor, 2- to 3-week event monitoring, or interrogation of an implanted
pacemaker was obtained at 6 and 12 months. The definition of success
for the procedure was no episodes of AF/left atrial flutter/atrial tachycardia
greater than 30 seconds. Patients were interviewed to determine resolution
or persistence of symptoms related to AF. Patient data were recorded con-
currently into a custom-computerized database. All patients were monitored
by a dedicated AF nurse specialist and the operating surgeon and electro-
physiologist. Preliminary 6-month data for a subset of these patients have
been published previously.16
RESULTS
FromMarch 2005 through January 2008, 52 patients with
paroxysmal AF underwent the described ablation procedure.
Patient demographics are listed in Table 1. All procedures
were completed as planned with no mortality or major com-
plications. The LAAwas excised or stapled in 44 (88.0%) of
50 patients. LAA exclusion was not performed if the opera-
tive surgeon deemed the LAA anatomy unsafe for endo-
scopic staple exclusion. There were no instances of
significant postoperative bleeding, heart block, or phrenicery c October 2010
FIGURE 1. Ganglionated plexi on the right side. RSPV, Right superior
pulmonary vein; RIPV, right interior pulmonary vein; SVC, superior vena
cava; IVC, inferior vena cava; RA, right atrium; LA, left atrium; R1–R13,
13 areas for ganglionated plexi on the right side.
TABLE 1. Patient demographics
Characteristics Results
AF type: Paroxysmal
No. of patients 52
Age (y) 60.3 (range, 42–79)
Gender
Male 35 (67.3%)
Female 17 (32.7%)
AF duration
<6 mo 1 (4.5%)
6–12 mo 0 (0.0%)
>1 y 42 (95.5%)
Ejection fraction 54.2 (range, 20–80)
Left atrial size 4.8 (range, 3.7–6.0)
Preoperative conditions
Unsuccessful AAD therapy (amiodarone/
sotalol/tikosin/rhythmol/flecanide)
31 (59.6%)
Previous cardioversion 19 (36.5%)
Warfarin intolerance/noncompliance 4 (9.8%)
Previous catheter ablation 10 (20.8%)
Preoperative pacemaker 12 (25.0%)
Previous cardiac surgery 9 (18.8%)
Coronary artery disease 9 (18.8%)
Mitral regurgitation
None 19 (39.6%)
Trace 6 (12.5%)
Mild 18 (37.5%)
Moderate 5 (10.4%)
Severe 0 (0.0%)
Previous transient ischemic attack 2.1%
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3–10 days). One case of temporary brachial plexus palsy
related to intraoperative patient positioning was observed.
Three patients required new postoperative permanent
pacemaker placement. The devices were placed for symp-FIGURE 2. Ganglionated plexi on the left side. LA, Left atrium; LV, left
ventricle; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary
vein; AV, atrioventricular; L1–L10; 10 areas for ganglionated plexi on the
left side.
Left atrial appendage isolation
Yes (amputation/stapling) 44 (88.0%)
AF, Atrial fibrillation; AAD, antiarrhythmic drug.
The Journal of Thoracic and Catomatic bradycardia in the setting of a sick sinus syndrome.
Two patients underwent additional electrophysiology abla-
tion procedures after the operation for right atrial flutter.
The patients were treated successfully and were free of
AF/atrial flutter/atrial tachycardia by LTM at 12months. De-
spite the success of the cardioversion, ablation was classed
as a failure in these patients because flutter and fibrillation
are both considered as failures of the procedure.
Long-term rhythmmonitoring modalities (LTM) used at 6
months were 24-hour Holter monitor (16/51; 31.4%), 14-
day event recorder (26/51; 51.0%), and pacemaker interro-
gation (9/51; 17.7%).*
Long-term rhythm monitoring modalities (LTM) used at
12 months were 24-hour Holter monitor (5/52; 9.6%), 14-
day event recorder (33/52; 63.5%), and pacemaker interro-
gation (14/52; 26.9%).
Maintenance of normal sinus rhythm as demonstrated by
LTM was 86.3% (44/51) at 6 months and 80.8% (42/52)*One patient at 6 months felt so good that she refused to wear a monitor. She did agree
to the 12-month LTM follow-up.
rdiovascular Surgery c Volume 140, Number 4 825
TABLE 2. Outcomes at 6 and 12 months by ECG and LTM
ECG LTM
6 moNSR 100% (50/50) 86.3% (44/51)
NSRþoff AAD 77.6% (38/49) 81.4% (35/43)
12 moNSR 88.5% (46/52) 80.8% (42/52)
NSRþoff AAD 87.8% (36/41) 89.2% (33/37)
ECG, Electrocardiogram; LTM, long-term monitoring; NSR, normal sinus rhythm;
AAD, antiarrhythmic drug.
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a success as defined by LTM, 81.4% (35/43) were not re-
ceiving AADs at 6 months and 89.2% (33/37) at 12 months.
It should be noted that their preprocedure AAD dosing reg-
imens were not altered after the procedure, unless they were
stopped. In compliance with the HRS/EHRA/ECAS expert
consensus statement AADs included the use of amiodarone,
sotalol, or flecanide.15 Beta-blockers per say were not con-
sidered AADs. Of note, there was no attempt to discontinue
AADs before the 6-month visit per follow-up protocol for
this study. This lowered our clinical success rate off AAD
at 6 months compared with 12 months (patients were gener-
ally taken off AAD at the 6-month visit, if appropriate).
Clinical symptoms attributed to AF were present in all
patients before this procedure. Fifty patients at 6 months
and 47 patients at 12 months completed the follow-up symp-
tom surveys. Symptoms recorded as significant included
fatigue, dyspnea, and palpitations. At 6 months and
12 months, 78.0% (39/50) and 63.8% (30/47) of patients
were symptom-free, respectively. Interestingly, only 3 of
the 11 symptomatic patients had clinical failure on LTM at
6 months, whereas 8 of the 17 symptomatic patients had
clinical failure at 12 months. Of the 7 patients in AF on
LTM at 6 months, 57.1% (4) reported they were without
symptoms. The decision to discontinue the use of warfarin
after clinical success was contingent on individual physician
preference. At 12 months, 81.1% (30/37) of the patients
deemed to have had clinically successful ablation by LTM
were not receiving warfarin.
We also compared LTM results at 6 and 12 months for
each patient. Of 7 patients in AF at 6 months by LTM, 3
(42.9%) were recorded as having normal sinus rhythm on
LTM at 12months. Conversely, 13.6% (6/44) of the patients
who were noted to be in normal sinus rhythm at 6 months on
LTM were later noted to have reverted to AF at 12 months’
follow-up with LTM.
DISCUSSION
This study demonstrates the feasibility and efficacy at 1
year of a minimally invasive surgical epicardial approach
to the management of patients with paroxysmal AF. A num-
ber of aspects of this procedure are worthy of discussion.
Core components of the procedure include bilateral pulmo-
nary vein antral isolation with intraoperative documentation
of block, detection of GPs with focal ablation, and excision826 The Journal of Thoracic and Cardiovascular Surgof the LAA. It is our experience that documentation of con-
duction block is critical to the success of the procedure. Mul-
tiple applications of the energy source may be required to
achieve entrance block. Because the veins may not be
blocked with a single application, intraoperative testing for
complete pulmonary vein isolation is critical for success.
Whether acute block translates into chronic block cannot
be determined within the confines of this study, but demon-
stration of acute entrance or exit block should be amandatory
component of the procedure. We used entrance block rather
than exit block to be indicative of transmurality inasmuch as
the mapping for GPs frequently stimulated the patients into
AF. Use of entrance rather than exit block testing precludes
the necessity for repeated intraoperative cardioversions.
The role of ablation of GPs in the management of AF con-
tinues to be debated.11,17 We performed mapping and abla-
tion of GPs in all patients without randomization; therefore,
it is not possible to know whether this contributed to the
overall success rate of the procedure. Owing to the limita-
tions of the current study, we cannot be certain that the tar-
geted cell bodies were ablated. If only the axon was ablated
and the nerve cell body remained viable, it is possible that
subsequent reinervation may contribute to late failure. In-
deed, we did have patients in whom ablation was a success
at 6 months and a failure at 12 months. To help elucidate the
role of the autonomic denervation with possible reinervation
of the left atrium on success of ablation of AF, we have now
initiated a program of performing full autonomic testing pre-
operatively and at 6 and 12 months postoperatively.
A component of this procedure was excision or exclusion
of the LAA. Inasmuch as this was believed to be the most
dangerous portion of the procedure to perform, we opted
to leave the LAA intact in those patients in whom exclusion
was believed to be high risk. Generally these were patients
with friable tissues and a wide-based and short LAA.
Although it is intuitive to surmise that exclusion of the
LAA lowers the thromboembolic risk independent of the
rhythm, that is by no means clear.18 Many patients have
a strong desire to stop receiving anticoagulants. We stopped
anticoagulant therapy in nearly 82% of our patients who
were free of AF at 6 months and had no LAA. Discomfort
with anticoagulant cessation on the part of the referring phy-
sician led to its continuance in a number of patients. Of note,
there were no postoperative transient ischemic attacks or
cerebrovascular accidents in this study. We are specifically
interested in the role of warfarin cessation in patients with
Cholesterol, Hypertension and Diabetes Study (CHADS)
scores of 2 or greater after successful surgical AF ablation.1
This we hope will be answered in the setting of a multicenter
trial of surgical ablation of paroxsysmal AF that is now
ongoing.
This study also highlights the parameters to be used for
defining ‘‘success.’’ We used the recent Heart Rhythm
Society guidelines of no episodes of AF of greater thanery c October 2010
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use of isolated clinical follow-up or isolated interval electro-
cardiograms overestimates the success rate relative to
rhythm detection by more intensive monitoring methods.
In fact, had we determined success by interval electrocardi-
ography, our success rate would have been 100% at 6
months’ follow-up.
One could argue, however, that if the indication for the
procedure is clinical symptoms and symptoms are relieved,
the relevance of rhythm documentation is doubtful. Our data
would argue against this assertion. It is remarkable that of
the 11 patients with continued symptoms at 6 months,
only 3 had clinical failure of ablation as defined by LTM.
At 12 months only 8 patients of 17 with continued
symptoms had clinical failure by LTM. Moreover, of the
7 patients with LTM failure at 6 months, only 3 (42.9%)
were symptomatic. This point highlights the lack of utility
of clinical symptoms when making clinical management de-
cisions for patients with paroxsysmal AF. Prior studies have
shown that ‘‘palpitations’’ are often the result of atrial or
ventricular premature beats and not recurrent AF.19 Obtain-
ing an accurate assessment of the efficacy of catheter and
surgical ablation for the treatment of AF is quite difficult
when reviewing the current medical literature. Reported
series of single-procedure catheter-based pulmonary vein
isolation used for the treatment of paroxsysmal AF vary
widely in efficacy from 38% to 78%. Methods of rhythm
evaluation between studies also vary widely,15 as did the
definition of ‘‘success’’ used to determine outcomes. Even
with our study’s adherence to the Heart Rhythm Society’s
reporting guidelines and use of LTM, our outcomes com-
pare favorably with studies of catheter-based pulmonary
vein isolation, even those using less stringent criteria for
success and less intense monitoring.
Limitations
This study included only patients with paroxysmal AF,
and the results cannot be extrapolated to persistent or
long-standing persistent AF in which substrate remodeling
occurs.20,21 From our experience in these latter patients,
the success rate is not as high and a more extensive set of ab-
lation lines is necessary.
This study was not randomized to continuation of AADs;
hence, the procedure’s true efficacy cannot be determined
with certainty. However, by our 12-month follow-up evalu-
ation, 90% of patients deemed to have had a clinically suc-
cessful ablation by LTM were receiving no AADs. This fact
would argue against a major confounding bias of AADs. It is
therefore likely that a treatment benefit resulted. It is also not
known whether success at 1 year translates to longer term
freedom from AF. In accordance with the Heart Rhythm So-
ciety’s reporting guidelines, we plan annual follow-up with
monitoring to determine this. This study also comprised
a relatively small number of patients; whether these resultsThe Journal of Thoracic and Caare reproducible in larger cohorts of patients is unknown.
The relative benefit of this procedure compared with catheter
ablation is also unknown. Inasmuch as success rates of serial
catheter-based ablations are reported to approach these re-
sults, a randomized trial of the 2 approaches is probably
now appropriate.
In this study we chose to include patients who had a pre-
vious cardioversion, because when examined for the study,
they exhibited typical paroxysmal pattern AF. The consen-
sus statement includes the statement, ‘‘As noted in the
ACC/AHA/ESC 2006 Guidelines, it is recognized that a par-
ticular patient may have AF episodes that fall into one or
more of these categories. It is recommended that patients
be categorized by their most frequent pattern of AF.’’ This
describes these patients—repeated intermittent episodes of
more than 30 seconds characteristic of paroxysmal AF.
Also, by including the patients in whom normal sinus
rhythm had failed to develop despite an earlier cardioversion
attempt, we are using a patient group that represents a greater
challenge for the surgical ablation procedure andmay reduce
our success rate.
CONCLUSIONS
Minimally invasive surgical ablation is effective in the
management of paroxysmal AF as evidenced by freedom
from atrial arrythmias by scheduled LTM at 6 months and
1 year. The use of electrocardiographic analysis alone over-
estimated success by up to 15%. The use of clinical symp-
toms underestimated clinical success as compared with
LTM.
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